Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MediciNova Inc
MNOV | US
1.41
USD-0.03
-2.08%
MNOV | US
About MediciNova Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
1.41
Open
1.49
High
1.49
Low
1.41
MediciNova Inc. a biopharmaceutical company focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast) an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders such as primary and secondary progressive multiple sclerosis amyotrophic lateral sclerosis chemotherapy-induced peripheral neuropathy degenerative cervical myelopathy glioblastoma and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine) a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast) an orally bioavailable small molecule compound to treat fibrotic and other diseases including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin) a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co. Ltd.; Kyorin Pharmaceutical Co. Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla California.
View LessMNOV | US
Risk
66.9
Sharpe
0.09
Luna's Score
49/100
Recommendation
Hold
Luna says (MNOV | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
42.0%1 month
66.9%3 months
68.2%6 months
84.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.54
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-2.65
Ent. to rev.
44.38
PEG
-0.94
Other Fundamentals
EBITDA
-9.80M
MarketCap
69.16M
MarketCap(USD)
69.16M
Div. yield
-
Op. margin
-981.95
Erngs. growth
-
Rev. growth
-
Ret. on equity
-13.32
Short ratio
2.47
Short perc.
0.47
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.17
Range1M
0.21
Range3M
0.63
Volumes: Market Activity
Rel. volume
0.93
Price X volume
82.32K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.65 | - | Cheaper |
| Ent. to Revenue | 44.38 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.54 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 68.20 | - | Par |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 69.16M | - | Emerging |
